Development and regulation of IL-17 producing cells during inflammation

The immune system has evolved to protect mammals from environmental stress factors such as pathogens. It functions as a fine-tuned consortium of effector units and suppressors. However, under certain pathologic conditions effector units may escape control and start to attack their own body. This leads to the development of autoimmune diseases, such as multiple sclerosis (MS). We use molecular and genetic tools such as Cre-recombinase and Cre/loxP, microscopy, next generation sequencing (including single cell sequencing and ATAC-seq), proteomics, and high dimensional flow cytometry to study the cellular and molecular mechanisms of MS pathology.

Research website

Position

Since 2011: W3 Univ. Prof. and Director, Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg-University, Mainz
2010-2011: Acting Director, Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg-University, Mainz
2005-2010: W2 Univ. Prof. in the I. Medical Department, University Medical Center of the Johannes Gutenberg-University, Mainz
2001-2005: Independent Group Leader, Laboratory for Molecular Immunology, Institute for Genetics, University of Cologne, Cologne, Germany
2000-2001: Research Associate, Department of Immunology, Institute for Genetics, University of Cologne, Cologne, Germany
1996-2000: Post-Doctoral fellow, Department of Immunology, Institute for Genetics, University of Cologne, (K. Rajewsky), Cologne, Germany
1994-1996: Post-Doctoral fellow, Department of Immunology, The Weizmann Institute of Science, (L. Steinman), Rehovot, Israel

Education

1986-1990: Ph.D. with E. Mozes, Department of Chemical Immunology, The Weizmann Institute of Science, Rehovot, Israel
1986-1988: M.Sc. with Y. Aloni and O. Laub, Department of Genetics, The Weizmann Institute of Science, Rehovot, Israel
1983-1986: B.Sc. Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv, Israel

 

Selected publications by Ari Waisman

  1. Waisman A, Ebering A (2019) Unraveling the T-B tangle in anti-CD20 multiple sclerosis therapy. Proc Natl Acad Sci U S A, 116(51):25376-25377 Link

  2. Kitic M, See P, Bruttger J, Ginhoux F, Waisman A (2019) Novel Microglia Depletion Systems: A Genetic Approach Utilizing Conditional Diphtheria Toxin Receptor Expression and a Pharmacological Model Based on the Blocking of Macrophage Colony-Stimulating Factor 1 Receptor. Methods Mol Biol, 2034:217-230 Link

  3. Wanke F, Tang Y, Gronke K, Klebow S, Moos S, Hauptmann J, Shanmugavadivu A, Regen T, Mufazalov IA, Gabriel LA, Reißig S, Diefenbach A, Kurschus FC, Waisman A (2018) Expression of IL-17F is associated with non-pathogenic Th17 cells. J Mol Med (Berl), 96:819–829 Link

  4. Turnescu T, Arter J, Reiprich S, Tamm ER, Waisman A, Wegner M (2017) Sox8 and Sox10 jointly maintain myelin gene expression in oligodendrocytes. Glia, 66(2):279-294 Link

  5. Mufazalov IA, Schelmbauer C, Regen T, Kuschmann J, Wanke F, Gabriel LA, Hauptmann J, Müller W, Pinteaux E, Kurschus FC, Waisman A (2017) IL-1 signaling is critical for expansion but not generation of autoreactive GM-CSF+ Th17 cells. EMBO J, 36, 102-115 Link